ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ELTX
MREO (37) BMEA (30) ATNM (43) DWTX (38) ⌘ Pro Terminal →

Elicio Therapeutics Inc. (ELTX) — RQD Stock Rating Cockpit

$1.59 -5.36% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.57

Elicio Therapeutics Inc. (ELTX) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $45.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ELTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ELTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Elicio Therapeutics Inc. (NASDAQ: ELTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.59 (-5.36% 1D, market cap $45.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ELTX ranks #866 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ELTX compare to MREO and BMEA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELTX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M) and BMEA (Biomea Fusion Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M). Among the 5-stock peer group, ELTX leads on earnings multiple (N/A) while DWTX leads on capital efficiency (-32.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ELTX?
▼

Per ELTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001601485), Elicio Therapeutics Inc. generated $105.6M in revenue (-16.2% YoY), -$39.6M in net income, and -$37.0M in free cash flow against $25.9M in total assets and $9.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.57 (-1.15%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510028
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (6)Whales (3)SEC (8)Macro (6)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-13.2% Base Target
$17 Bull$1 Base$1 Bear
📬 FREE ELTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY ELTX SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$1.77-11.3% Next Q
Q2 (-2Q)
33
Grade E$1.57+16.6% Next Q
Q3 (-1Q)
31
Grade E$1.83-13.1% Next Q
Current
28
Grade E$1.59-10% Hist 90D α
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ELTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ELTX currently carries a cautious 28/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.01) and Max Pain ($1.67) forces dealer call-delta covering toward $16.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ELTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
42.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $1$1.59H: $16
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 14 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on ELTX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (23)

8/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like ELTX
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELTX)

  • ✓Walkthrough of ELTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ELTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -85.24%⚡ TESTING RESISTANCE
2026-11-03O $1.75H $1.75L $1.59C $1.59VOL 183.9K
RES: $1.77SUP: $1.24SMA50: $2.01SMA200: $6.72
$17.02$12.80$8.57$4.35$0.13RES $1.77SUP $1.24$1.592026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ELTX Butterfly Map → + Track ELTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -16.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ELTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ELTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ELTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELTX)

Health Care Rank #866 of 1015 ⚔️ MREO vs ELTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ELTX vs. MREO, BMEA, ATNM, DWTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Elicio Therapeutics Inc. (ELTX) ranks #866 by composite RQD confidence (28/100, grade E) and #759 by equity capitalization ($45.5M). Within this direct 5-issuer industry benchmark cohort, ELTX leads on earnings valuation at N/A trailing P/E, while DWTX leads on capital efficiency and profitability with -32.3% ROIC and — gross margin. ATNM currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ELTX at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ELTX ACTIVE
Elicio Therapeutics Inc.
E 28/100 — — -35.0% -5.36% $45.5M Benchmark Subject
MREO
Mereo BioPharma Group plc
D- 37/100 — — -35.0% +0.17% $46.2M /mreo-vs-eltx →
BMEA
Biomea Fusion Inc.
E 30/100 — — -35.0% +3.19% $46.4M /bmea-vs-eltx →
ATNM
Actinium Pharmaceuticals Inc. (Delaware)
D- 43/100 — — -35.0% -3.38% $46.5M /atnm-vs-eltx →
DWTX
Dogwood Therapeutics Inc.
D- 38/100 — — -32.3% -4.69% $43.5M /dwtx-vs-eltx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001601485 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elicio Therapeutics Inc. (ELTX) reported GAAP revenue of $105.6M (-16.2% vs. FY2024 revenue of $126.0M , and +5.5% cumulative change since FY2023) , GAAP net income of -$39.6M, operating cash flow of -$37.0M, and free cash flow of -$37.0M (+0.5% YoY). On the balance sheet, ELTX closed FY2025 with $25.9M in total assets against $9.4M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $105.6M -$39.6M -$37.0M -$37.0M $25.9M $9.4M
FY2024 (FY) 2024-12-31 $126.0M -$51.9M -$37.1M -$37.2M $28.2M $20.0M
FY2023 (FY) 2023-12-31 $100.1M -$35.2M -$32.7M -$32.7M — —

3. ELTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Elicio Therapeutics Inc. (NASDAQ: ELTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.59 (-5.36% 1D, market cap $45.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ELTX ranks #866 in composite RQD confidence.

How does ELTX compare to MREO and BMEA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELTX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M) and BMEA (Biomea Fusion Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M). Among the 5-stock peer group, ELTX leads on earnings multiple (N/A) while DWTX leads on capital efficiency (-32.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ELTX?

Per ELTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001601485), Elicio Therapeutics Inc. generated $105.6M in revenue (-16.2% YoY), -$39.6M in net income, and -$37.0M in free cash flow against $25.9M in total assets and $9.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ELTX trading relative to its 50-day, 200-day, and 52-week technical levels?

ELTX last traded at $1.59 (-5.36% on volume of 330,717 shares), positioning the stock -20.90% below its 50-day simple moving average ($2.01) and -76.34% below its 200-day simple moving average ($6.72). Across its 52-week range of $1.44 to $16.00, ELTX sits at the 1.0% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.39 to $1.79).

Direct Sub-Reports: ELTX RQD Cockpit ELTX 12M Forecast ELTX Earnings & Move ELTX Dividends & DRIP ELTX Insiders & 13F ELTX Whale Options ELTX Profit Sankey ELTX News & Why
ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

ELTX — Elicio Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Elicio Therapeutics Inc. (ELTX) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.59 (-5.36% 1D, market capitalization $45.5M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of 5.75x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Elicio Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue for FY 2025 and FY 2024 is — in each period indicating no reported revenue in those years. — for how the company monetizes its activities.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Elicio Therapeutics Inc. (ELTX) reported $105.6M in annual revenue (up from $126.0M in FY2024, -16.2% YoY) and -$39.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($100.1M revenue, -$35.2M net income) through FY2025, ELTX scaled operating cash flow to -$37.0M and free cash flow to -$37.0M, backed by $25.9M in total assets against $9.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.44 – $16.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ELTX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can ELTX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $105.6M and free cash flow of -$37.0M, how will capital allocation balance growth reinvestment against $9.4M in total debt?
  • Key Question #3: How sensitive is ELTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ELTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Elicio Therapeutics Inc. (ELTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ELTX Debate Forum (3) ↓
🟡 MARKET WIRE Benzinga • 5d ago
Elicio Therapeutics To Demonstrate Data Of Two Poster Presentations For Its Phase 2 AMPLIFY-7P Trial Of Camupepimut , Expanded Antigen-Agnostic Intratumoral Application Of AMP-Adjuvant Platform At Society For Immunotherapy Of Cancer's Annual Meeting

Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ELTX Bull vs. Bear Conversation Board — What's Your Call at $1.59?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ELTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ELTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $2.03 (+20.8%)
📌 Pinned Debate

Phase 2 AMPLIFY-7P results are slated for presentation at ESMO Congress 2026 and SITC 2026 with a simultaneous Nature Medicine publicat

Phase 2 AMPLIFY-7P results are slated for presentation at ESMO Congress 2026 and SITC 2026 with a simultaneous Nature Medicine publication, offering a potential clinical catalyst.. When you look under the hood at ELTX, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $16.00. My 12M target is $2.03.

SectorRotator 🐂 BULL

@AlphaFlow_Cap Agree on the RQD 28/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.68 and keeping dry powder in case we test $1.56.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $1.33 (-20.8%)
Spot @ $1.68

With FY 2025 FCF of -$37.0M against $18.6M in cash and zero reported revenue, the company's cash engine scores 6/20 in the RQD rating.

Fading this rally in ELTX at $1.68. With FY 2025 FCF of -$37.0M against $18.6M in cash and zero reported revenue, the company's cash engine scores 6/20 in the RQD rating.. With a beta of 1.0 and the stock sitting at $1.68 (52-wk range $1.44–$16.00), the easy multiple expansion is already priced in.

LIVE TAPE